Skip to main content
. 2019 Jan 25;14(1):e0211433. doi: 10.1371/journal.pone.0211433

Fig 5.

Fig 5

Vasomotor effect of cumulative dose-dependent administration of: Maxadilan (a); Ala11,22,28VIP (b); and Bay55-9837 (c) in carotid artery; and Maxadilan (d); Ala11,22,28VIP (e); and Bay55-9837 (f) in femoral artery of wild type (WT) and PACAP knockout (KO) mice, and their effect in the presence of M65 (PAC1R antagonist) (a and d) and VIP6-28 (VPAC1R antagonist) (b and e). Arterial relaxation is marked as negative change in force. Data are expressed as means ± SEM (n = 3-6/group). *p < 0.05 WT vs. KO; #p < 0.05 WT vs. baseline; Δp < 0.05 KO vs. baseline; $p < 0.05 WT+antagonist vs. baseline; †p < 0.05 KO+antagonist vs. baseline; ‡p < 0.05 WT vs. WT+antagonist; §p < 0.05 KO vs. KO+antagonist.